FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1242074059> ?p ?o ?g. }

• W1242074059 abstract "Introduction: Schizophrenia is a devastating mental illness that impairs mental and social functioning and often leads to the development of co-morbid diseases. They are at greater risk for metabolic dysfunctions than other individuals due to a number of reasons, including inactive lifestyle, poor dietary choices, and side effects of antipsychotic medications. Atypical antipsychotics were reported to be associated with increased risk of hyperglycaemia and hyperlipidemia, and subsequently increase the risk of metabolic syndrome. However, ziprasidone and aripiprazole have a favourable metabolic profile.Objectives: i) To determine the prevalence of metabolic syndrome and its components among schizophrenia patients. ii) To determine the improvement and reversibility of metabolic syndrome, its components and lipid profiles after switching to aripiprazole or ziprasidone. iii) To determine the safety and efficacy of aripiprazole and ziprasidone in the treatment of schizophrenia patients with metabolic syndrome.Methodology:Screening -The study was conducted at four mental institutions and four general hospitals. Study population were schizophrenia patients aged between 18 and 65 years old, who met the DSM-IV TR criteria for schizophrenia. Patients should receive antipsychotic treatment for at least 1 year and were not on mood stabilizer. Metabolic syndrome was defined by using the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria-modified for Asian waist circumference.Randomized double-blind controlled trial was conducted for 6-month after screening.The dose of aripiprazole and ziprasidone, can be either increased or reduced based on clinical assessment. The total daily dosage of ziprasidone ranges from 80mg - 160mg.The total daily dosage of aripiprazole ranges from 10mg - 30 mg. The outcome measures included body mass index (BMI), waist circumference, bloodvpressure(BP), fasting blood sugar (FBS) and lipid profile, adverse effects monitoring and clinical rating scale such as Positive and Negative Symptoms Scale (PANSS), Clinical Global Impression Scale (CGI), Abnormal Involuntary Movement Scale (AIMS), Barnes Akathasia Scale (BAS) and Simpson Angus Scale (SAS).Intention-to-treat analysis and mixed-effects model with repeated measures (MMRM) for statistical analysis were done.Results: A total of 527 patients were screened but only 270 schizophrenia patients fulfil all inclusion and did not have any exclusion criteria. The prevalence of metabolic syndrome was 46.7%. There was improvement in the prevalence of all metabolic syndrome component from baseline to 6-month after switching to aripiprazole or ziprasidone; waist circumference (aripiprazole 84.4% vs. 44.4%, ziprasizone 87.1% vs. 35.3%), HDL cholesterol (aripiprazole 54.4% vs. 33.3%, ziprasizone 52.9% vs. 23.5%), triglycerides (aripiprazole 50.0% vs. 21.1%, ziprasizone 37.6% vs. 12.9%), BP (aripiprazole 41.1% vs. 25.6%, ziprasizone 32.9% vs. 20.0%), FBS (aripiprazole 42.2% vs. 20.0%, ziprasizone 25.9% vs. 8.2%, p<0.05). Switching to either aripiprazole or ziprasidone cause statistically significant reduction in prevalence of metabolic syndrome after 6 month of treatment (aripiprazole 58.9% vs. 30.0%, ziprasizone 51.8% vs. 15.3%, p<0.05). There was statistically significant improvement in PANSS, CGI, BARS and SAS after switching to aripiprazole or ziprasidone.Conclusion: The prevalence of metabolic syndrome in schizophrenia patients receiving antipsychotic in Malaysia was very high. Switching to aripiprazole or ziprazidone was effective in reversing the metabolic syndrome and its components among schizophrenia patients who had metabolic syndrome." @default.
• W1242074059 created "2016-06-24" @default.
• W1242074059 creator A5038220824 @default.
• W1242074059 date "2013-01-01" @default.
• W1242074059 modified "2023-09-23" @default.
• W1242074059 title "Efficacy of switching to aripiprazole and ziprasidone on clinical and metabolic profile among schizophrenic patients with metabolic syndrome / Mas Ayu Binti Said" @default.
• W1242074059 hasPublicationYear "2013" @default.
• W1242074059 type Work @default.
• W1242074059 sameAs 1242074059 @default.
• W1242074059 citedByCount "0" @default.
• W1242074059 crossrefType "dissertation" @default.
• W1242074059 hasAuthorship W1242074059A5038220824 @default.
• W1242074059 hasConcept C118552586 @default.
• W1242074059 hasConcept C126322002 @default.
• W1242074059 hasConcept C134018914 @default.
• W1242074059 hasConcept C15744967 @default.
• W1242074059 hasConcept C2776412080 @default.
• W1242074059 hasConcept C2776921671 @default.
• W1242074059 hasConcept C2777270317 @default.
• W1242074059 hasConcept C2780211496 @default.
• W1242074059 hasConcept C2780494398 @default.
• W1242074059 hasConcept C2780578515 @default.
• W1242074059 hasConcept C2908647359 @default.
• W1242074059 hasConcept C511355011 @default.
• W1242074059 hasConcept C71924100 @default.
• W1242074059 hasConcept C99454951 @default.
• W1242074059 hasConceptScore W1242074059C118552586 @default.
• W1242074059 hasConceptScore W1242074059C126322002 @default.
• W1242074059 hasConceptScore W1242074059C134018914 @default.
• W1242074059 hasConceptScore W1242074059C15744967 @default.
• W1242074059 hasConceptScore W1242074059C2776412080 @default.
• W1242074059 hasConceptScore W1242074059C2776921671 @default.
• W1242074059 hasConceptScore W1242074059C2777270317 @default.
• W1242074059 hasConceptScore W1242074059C2780211496 @default.
• W1242074059 hasConceptScore W1242074059C2780494398 @default.
• W1242074059 hasConceptScore W1242074059C2780578515 @default.
• W1242074059 hasConceptScore W1242074059C2908647359 @default.
• W1242074059 hasConceptScore W1242074059C511355011 @default.
• W1242074059 hasConceptScore W1242074059C71924100 @default.
• W1242074059 hasConceptScore W1242074059C99454951 @default.
• W1242074059 hasLocation W12420740591 @default.
• W1242074059 hasOpenAccess W1242074059 @default.
• W1242074059 hasPrimaryLocation W12420740591 @default.
• W1242074059 hasRelatedWork W1845853025 @default.
• W1242074059 hasRelatedWork W1875134139 @default.
• W1242074059 hasRelatedWork W1973927961 @default.
• W1242074059 hasRelatedWork W1981169165 @default.
• W1242074059 hasRelatedWork W1994877202 @default.
• W1242074059 hasRelatedWork W2017249848 @default.
• W1242074059 hasRelatedWork W2022211242 @default.
• W1242074059 hasRelatedWork W2034968091 @default.
• W1242074059 hasRelatedWork W2078650063 @default.
• W1242074059 hasRelatedWork W2086436655 @default.
• W1242074059 hasRelatedWork W2086790654 @default.
• W1242074059 hasRelatedWork W2164714146 @default.
• W1242074059 hasRelatedWork W2335570871 @default.
• W1242074059 hasRelatedWork W2350981989 @default.
• W1242074059 hasRelatedWork W2363263598 @default.
• W1242074059 hasRelatedWork W2380106938 @default.
• W1242074059 hasRelatedWork W2733694618 @default.
• W1242074059 hasRelatedWork W2765393806 @default.
• W1242074059 hasRelatedWork W3031930111 @default.
• W1242074059 hasRelatedWork W3206180250 @default.
• W1242074059 isParatext "false" @default.
• W1242074059 isRetracted "false" @default.
• W1242074059 magId "1242074059" @default.
• W1242074059 workType "dissertation" @default.